Current stock page

Financial Data

URGN Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

URGNUroGen Pharma Ltd.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$26.18−$0.21 (−0.80%)

Latest quote

  • Momentum
    40
  • Value
    64
  • Quality
    68
  • Risk resilience
    40
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$89M$72.46M$50.96M$37.84M$27.48M$24.22M$20.25M$24.57M
Gross Profit$81.5M$65.88M$46.82M$34.55M$24.2M$20.67M$17.92M$22.09M
Operating Income$8.33M$111K-$20.26M-$19.12M-$27.39M-$41.45M-$36.91M-$27.66M
Net Income-$1.46M-$14.35M-$23.57M-$26.36M-$33.35M-$49.94M-$43.84M-$37.51M
EPS-$0.03-$0.28-$0.47-$0.54-$0.69-$1.05-$0.92-$0.8
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$15.2M-$33.01M-$45.32M-$38.33M-$42.27M-$39.83M-$42.02M-$13.62M
Capital Expenditure-$72K-$60K-$54K-$17K-$87K-$141K-$44K-$115K
Free Cash Flow-$15.27M-$33.07M-$45.37M-$38.34M-$42.36M-$39.97M-$42.07M-$13.73M
Net Cash Provided By Operating Activities-$15.2M-$33.01M-$45.32M-$38.33M-$42.27M-$39.83M-$42.02M-$13.62M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$271.87M$252.59M$253.69M$200.46M$185.05M$208.72M$247.62M$285.71M
Total Debt$196.28M$196.13M$197.09M$128.33M$129.94M$127.47M$124.95M$123.39M
Cash And Cash Equivalents$85.56M$79.13M$111.3M$110.75M$90.04M$92.9M$104.03M$171.99M
Total Liabilities$397.09M$384.99M$377.94M$305.93M$300.45M$302.09M$294.08M$294.51M
Total Stockholders Equity-$125.22M-$132.4M-$124.25M-$105.47M-$115.41M-$93.38M-$46.46M-$8.8M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio————————
P/S ratio5.29———————
Debt To Equity————————
Free Cash Flow Yield-10.15%-6.80%-12.60%-17.38%-12.21%-13.92%-20.33%-20.80%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio————————
P/S ratio5.29———————
Return On Equity————————
Debt To Equity————————

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-19.83x
Pb-10.57x
Revenue Growth Yoy223.85%
EPS Growth Yoy95.65%
Gross Margin91.41%
Operating Margin-12.36%
ROE53.97%
ROIC-15.47%
Debt To Equity-1.57
FCF Yield-10.28%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$26.18
Volume700,016
RSI (14)28.74
MACD-3.37
MACD signal-3.05
MACD histogram-0.33
ADX (14)45.14
SMA (50)$37.00
SMA (200)$31.69
ATR (14)$2.02
Historical volatility (annualized)79.44%
Volume (20-day average)1.26M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score40/100
Beta1.33
Annual volatility61.94%
Max Drawdown-50.79%
Sharpe Ratio0.39
VaR (95%, 1-day)-5.55%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

URGN Financial Data FAQ

What is UroGen Pharma Ltd.'s revenue?

UroGen Pharma Ltd.'s revenue is one of the core financial data points for URGN. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is UroGen Pharma Ltd.'s revenue growing?

Revenue growth shows whether UroGen Pharma Ltd. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is URGN's EPS?

URGN's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is UroGen Pharma Ltd.'s net income?

UroGen Pharma Ltd.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does UroGen Pharma Ltd. generate?

Free cash flow shows how much cash UroGen Pharma Ltd. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does UroGen Pharma Ltd. have?

Cash and debt help frame URGN's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.